Previous Close | 0.9196 |
Open | 0.9000 |
Bid | 0.8800 x 1000 |
Ask | 0.9500 x 1000 |
Day's Range | 0.8805 - 0.9500 |
52 Week Range | 0.7250 - 4.3400 |
Volume | |
Avg. Volume | 102,339 |
Market Cap | 1.834M |
Beta (5Y Monthly) | 1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.1500 |
Earnings Date | Apr 15, 2024 - Apr 19, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for NAOV
ELMSFORD, N.Y., March 28, 2024--NanoVibronix, Inc. (Nasdaq: NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc. ("Veranex") to assist with the development of the company’s next generation UroShield and PainShield products.
ELMSFORD, N.Y., December 06, 2023--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine in an article titled ‘UroShield Prevention is better than cure.’ The article highlights the effectiveness of using UroShield in the prevention of catheter associated urinary tract infe
ELMSFORD, N.Y., December 04, 2023--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the "LOI") with APOGEPHA Arzneimittel GmbH ("APOGEPHA") in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European